by Mark Curtis | Aug 11, 2014
. Welcome to your deal review for the month of July. There was financing activity this past month as StemCells and Fate Therapeutics each secured $20 million in funding. Bluebird bio was busy with the acquisition of a privately-held genome editing company; clearly a...
by Erin Sugar | Aug 8, 2014
. The following scene from Family Guy offers a glimpse into both the tone and subject matter of this week’s Right Turn. Being an avid lover of superheroes, monsters and all things supernatural, the topic of healing and limb regeneration has always been a subject I...
by Mark Curtis | Jul 21, 2014
. The Centre for Commercialization of Regenerative Medicine (CCRM) just finished hosting the 7th annual Business of Regenerative Medicine course here in Toronto, which saw many notable figures in the space come to weigh-in on a number of critical issues relevant to...
by Stacey Johnson | Jul 11, 2014
Stem cells as art is becoming a recurring theme on Signals. If you want to admire some beautiful stem cell art, there’s Klair Reis’ petri projects, Radha Chaddah’s beautiful photography here, and stem cell images are featured every week on Signals near the bottom of...
by Lisa Willemse | Jun 3, 2014
> Bench to beside is a deceptively simple phrase. Only 15 characters and relatively jargon-free (assuming you know what bench and bedside are referring to), it’s rather easy to drop into documents or presentations without compromising space or time limits. And,...
by Stacey Johnson | May 30, 2014
> CCRM’s intrepid communications summer student is back! Erin Sugar gets right to the meat of the issue in today’s Right Turn. Does it leave you hungry for more or salivating with anger? Sometimes, an ordinary encasement of all-beef or pork salami is just not going...
Comments